<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912416</url>
  </required_header>
  <id_info>
    <org_study_id>ProIron 16</org_study_id>
    <nct_id>NCT02912416</nct_id>
  </id_info>
  <brief_title>Efficacy of Probiotics on Iron Status During Pregnancy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the effect of probiotics on improving iron status in a population of healthy,
      pregnant women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum ferritin level</measure>
    <time_frame>Week 28 of gestation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Prevention of Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule with probiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, pregnant women, aged 18-42 years, with a singleton gestation

          -  Inclusion at 10-12 weeks of gestation

          -  BMI ≥ 18 and ≤ 30 at baseline

          -  Provide signed and dated informed consent form

          -  Willing to comply with all study procedures

        Exclusion Criteria:

          -  Serum ferritin level &lt;20 µg/L or Hb&lt;110 g/L at baseline (visit 1)

          -  Chronic diseases associated with anemia

          -  Known Thalassemia

          -  Hyperemesis gravidarum

          -  Chronic gastrointestinal disease (inflammable bowel diseases; Crohn's disease,
             Ulcerative Colitis; diarrheal disease)

          -  Known gluten intolerance, lactose intolerance, milk protein allergy

          -  Taking antibiotics within four weeks before inclusion

          -  Blood or plasma donation within three (3) months prior to baseline

          -  History of any clinically significant disease or disorder which, in the opinion of
             the Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  Smoking or use of nicotine-containing products (currently or during the last three
             [3] months)

          -  History of alcohol abuse, or excessive intake of alcohol, as judged by the
             Investigator

          -  Hypersensitivity to any of the ingredients in the study products

          -  Any other reason for exclusion, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lena Hulthén, Prof.</last_name>
    <phone>+46 31 786 3714</phone>
    <email>lena.hulthén@medfak.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>CuraÖresund</name>
      <address>
        <city>Malmö</city>
        <zip>205 12</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Sundler, MD</last_name>
      <phone>+46 40 615 0601</phone>
      <email>malin.sundler@ivfkliniken.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>September 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
